| Indicators | Browse All

Jasper Therapeutics, Inc. (JSPRW)

Redwood City, United States | NasdaqCM
0.00 USD 0.00 (-84.615%) ⇩ (Sept. 24, 2026, 3:59 p.m. EDT)

Short-term:⯪☆☆☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take ↕ | Oct. 10, 2026, 3:14 a.m. EDT

The security is effectively worthless for investment purposes, trading at a fraction of a cent with zero liquidity and no corporate actions to support a trade. There is no price history available to assess momentum or trend, and the lack of data renders any statistical forecasting useless. Fundamentally, the company reports massive losses with negative earnings per share and a book value that is irrelevant given the current price structure. Furthermore, there is no dividend history to suggest any income potential. This is a speculative penny stock with no catalysts, no earnings, and no capital preservation mechanism.

None
Attribute Value
Previous Name Kira Pharmaceuticals
Website https://jaspertx.com

Info Dump

Attribute Value
Address1 2,200 Bridge Pkwy
Address2 Suite #102
Ask 0.0
Ask Size 0
Bid 0.0
Bid Size 0
Book Value 0.05
City Redwood City
Country United States
Crypto Tradeable 0
Currency USD
Current Price 0.0002
Custom Price Alert Confidence HIGH
Day High 0.0039
Day Low 0.0001
Ebitda Margins 0.0
Eps Trailing Twelve Months -3.836
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 15
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Two Week High 0.0039
Fifty Two Week High Change -0.0037
Fifty Two Week High Change Percent -0.94871795
Fifty Two Week Low 0.0001
Fifty Two Week Low Change 0.0001
Fifty Two Week Low Change Percent 1.0
Fifty Two Week Range 1.0E-4 - 0.0039
Financial Currency USD
First Trade Date Milliseconds 1,784,295,000,000
Full Exchange Name NasdaqCM
Fullday Change -0.0011
Fullday Change Percent -84.61539
Fullday Price 0.0002
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Industry
Industry Key
Language en-US
Long Business Summary Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders. The company is based in Redwood City, California.
Long Name Jasper Therapeutics, Inc.
Market us_market
Market State PRE
Max Age 86,400
Message Board Id finmb_2010365309
Name Change Date 2,026-10-16
Open 0.08
Operating Margins 0.0
Phone 650-549-1400
Prev Name Kira Pharmaceuticals
Previous Close 0.0013
Price Hint 4
Price To Book 0.0039999997
Profit Margins 0.0
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.0011
Regular Market Change Percent -84.61539
Regular Market Day High 0.0039
Regular Market Day Low 0.0001
Regular Market Day Range 1.0E-4 - 0.0039
Regular Market Open 0.08
Regular Market Previous Close 0.0013
Regular Market Price 0.0002
Regular Market Time 1,790,279,960
Regular Market Volume 863,065
Sand P52 Week Change 0.16207206
Sector
Sector Key
Source Interval 15
State CA
Symbol JSPRW
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -3.836
Trailing Peg Ratio None
Triggerable 1
Type Disp Equity
Volume 863,065
Website https://jaspertx.com
Zip 94,065